MRKR Earnings Date & History
Marker Therapeutics Inc (NASDAQ NMS - GLOBAL MARKET) earnings schedule, consensus estimates and reported results for the last eight quarters.
Last updated Aug 19, 2026 at 7:36 PM ET
Marker Therapeutics Inc
Biotechnology
- Next earnings date
- Wednesday, November 11, 2026
- Reporting session
- Time TBD
- EPS estimate
- $-0.28
- Revenue estimate
- $695,640
MRKR earnings history
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Friday, May 15, 2026 | Q1 2026 | $-0.19 | $-0.16 | +14.4% | $752,000 |
| Wednesday, March 18, 2026 | Q4 2025 | $-0.20 | $-0.09 | +55.1% | $1.1M |
| Thursday, November 13, 2025 | Q3 2025 | $-0.46 | $-0.12 | +73.9% | $1.2M |
| Thursday, August 14, 2025 | Q2 2025 | $-0.42 | $-0.29 | +30.7% | $861,000 |
What the market is watching in MRKR's next report
- The full Earnings Read for this company: focus areas, peer read-through and prior-reaction context.
- Ticker Read combines trend, relative strength and catalysts in one research view.
- Scanners, Impact Radar and the members-only Weekly Watchlist are included.
Get the week's earnings by email
One free email each week: the reports that matter, when they land, and what the market is watching.
Frequently asked questions
- When is the next MRKR earnings date?
- Marker Therapeutics Inc is scheduled to report on Wednesday, November 11, 2026 (Time TBD). Dates can change until the company confirms them.
- Does MRKR report before or after the market?
- The next report is scheduled time tbd.
- What EPS is expected for MRKR?
- Consensus EPS for the upcoming quarter is $-0.28, on revenue of $695,640.
Calendar data is provided for educational and research purposes only and is not investment advice. Release dates, times, estimates and results can change; always verify against the issuing company or agency.
MRKR earnings discussion
Anyone can read. Any free Hyper Stocks account can join in.
Create a free account to join the discussion. Reading is open to everyone — commenting is free, no subscription needed.
Loading discussion…
Member comments are opinions from individual users, not Hyper Stocks research, and are never personalised investment advice.